Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS
Multiple Sclerosis, 06/29/09
Strober L et al. – The Rao Brief Repeatable Neuropsychological Battery (BRNB) and Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS). have comparable sensitivity among pts with multiple sclerosis (MS). Although the sensitivity of the auditory/verbal memory tests is similar, BVMTR appears more sensitive than the 10/36.
Methods- Study of the different memory tests of the BRNB and MACFIMS
- BRNB: Selective Reminding Test (SRT) and 10/36 Spatial Recall Test (10/36)
- MACFIMS: California Verbal Learning Test, Second Edition (CVLT2) and Brief Visuospatial Memory Test, Revised (BVMTR)
- Comparison of test sensitivity and their respective batteries in 65 MS pts and 46 demographically matched controls
- BRNB and MACFIMS comparable in overall sensitivity to disease status
- BVMTR showed greater discriminative validity than 10/36
- CVLT2 and SRT comparable in sensitivity
- SDMT most sensitive NP test across both batteries
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial : The Lancet
The Lancet - Early Online Publication, 10/08/09
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
The Lancet Neurology, 10/16/09
Sponsor
Article Search
Sponsor


See Latest Articles


